Cargando…
The addition of dydrogesterone improves the outcomes of pregnant women with low progesterone levels when receiving vaginal progesterone alone as luteal support in HRT‐FET cycles
PURPOSE: Vaginal progesterone (VP) alone has been used as luteal support (LS) in HRT‐FET cycles without measuring serum progesterone concentrations (SPC) because it can achieve adequate intrauterine progesterone levels. However, several reports showed that the co‐administration of progestin produced...
Autores principales: | Toriumi, Rena, Horikawa, Michiharu, Sato, Chie, Shimamura, Nagisa, Ishii, Rena, Terashima, Michiru, Hamada, Michiko, Tachibana, Naoyuki, Taketani, Yuji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10032329/ https://www.ncbi.nlm.nih.gov/pubmed/36969958 http://dx.doi.org/10.1002/rmb2.12511 |
Ejemplares similares
-
A novel orally active gonadotropin‐releasing hormone antagonist, relugolix, is a potential substitute for injectable GnRH antagonists in controlled ovarian stimulation in assisted reproductive technology
por: Hamada, Michiko, et al.
Publicado: (2021) -
Do early luteal serum progesterone levels predict the reproductive outcomes in IVF with oral dydrogesterone for luteal phase support?
por: Netter, Antoine, et al.
Publicado: (2019) -
Different anti‐Műllerian hormone (AMH) levels respond to distinct ovarian stimulation methods in assisted reproductive technology (ART): Clues to better ART outcomes
por: Ishii, Rena, et al.
Publicado: (2019) -
A Comparison of Oral Dydrogesterone with Vaginal Progesterone for Luteal-Phase Support in In vitro Fertilization: A Randomized Controlled Trial
por: Naghshineh, Elham, et al.
Publicado: (2023) -
Comparison of oral dydrogesterone with suppository vaginal progesterone for luteal-phase support in in vitro fertilization (IVF): A randomized clinical trial
por: Salehpour, Saghar, et al.
Publicado: (2013)